clinical trial · NCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Akeso·phase3·recruiting·n = 560
NSCLC (Non-small Cell Lung Cancer)Cadonilimab (AK104)Sugemalimab
brief summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
started
Nov 12, 2024
primary completion
Oct 28, 2026
completion
Dec 30, 2028
last updated
Mar 12, 2025
official title
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol